Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epirubicin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cisplatin / Capecitabine | EXPERIMENTAL | Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks. |
| Epirubicin / Cisplatin / Capecitabine | EXPERIMENTAL | Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks. |
| Epirubicin / Oxaliplatin / Capecitabine | EXPERIMENTAL | Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks. |
| Docetaxel / Cisplatin / Capecitabine | EXPERIMENTAL | Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Cisplatin | DRUG | 80 mg/m2/day, intravenous (IV), every 3 weeks |
| Capecitabine | DRUG | 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle |
| Epirubicin | DRUG | 50 mg/m2/day, IV, every 3 weeks |
| Oxaliplatin | DRUG | 130 mg/m2/day, IV, every 3 weeks |
| Docetaxel | DRUG | 60 mg/m2/day, IV, every 3 weeks |
Inclusion Criteria: * adult patients, \>=18 years of age; * advanced or metastatic gastric cancer; * Eastern Cooperative Oncology Group (ECOG) \<=2. Exclusion Criteria: * previous chemotherapy (except adjuvant or neoadjuvant treatment \>=6 months prior to study); * evidence of central nervous sys...
Top 20 of 45 competitors
Epirubicin is an oncology small molecule being studied for use in gastric cancer. In clinical development, it is being evaluated in combination with other chemotherapy agents for patients with advanced and/or metastatic gastric cancer. The drug is currently in Phase 2 clinical trials for this indication.
Epirubicin is a small molecule oncology drug. Its specific molecular target is not disclosed in the available clinical trial information. The drug is being studied in combination with capecitabine and other chemotherapy for the treatment of advanced and/or metastatic gastric cancer.
Epirubicin is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on the drug for the treatment of gastric cancer.
Epirubicin is in Phase 2 clinical development for gastric cancer. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, with no active trials currently ongoing.
Epirubicin has been studied in one completed Phase 2 clinical trial, NCT00454636. This trial evaluated capecitabine in combination with chemotherapy, including epirubicin, in 158 patients with advanced and/or metastatic gastric cancer. The study was conducted in Spain and enrolled adults aged 18 years and older.
Epirubicin is not known to have alternative names in the available clinical trial information. It is being studied as a distinct chemotherapy agent in combination regimens for gastric cancer.